
What smart money is saying about Revvity, Inc.
2 funds in our archive have pitched Revvity, Inc. — most recently EdgePoint Global Portfolio in June 2026.
Revvity, Inc., founded in 1937 and based in Waltham, Massachusetts, is a global enterprise that develops and delivers a wide array of products, services, and solutions. The company, which changed its name from PerkinElmer, Inc. in April 2023, caters to the diagnostics, life sciences, and applied services sectors worldwide. Its Discovery & Analytical Solutions division provides advanced instrumentation, reagents, informatics, software, subscriptions, and sophisticated detection and imaging technologies. These resources are designed to enable scientists to achieve significant breakthroughs in life sciences research. This segment also offers contract research and specialized laboratory services. Furthermore, it supplies analytical tools and services for assessing environmental health, including air, water, and soil, and delivers solutions to agricultural and food producers. It also serves the industrial market with analytical instrumentation for sectors such as chemical, semiconductor, electronics, energy, lubricants, petrochemicals, and polymers. The Diagnostics segment is dedicated to early detection, offering instruments, reagents, assay platforms, and software for identifying genetic disorders in pregnant individuals and young children, alongside infectious disease testing. Its products facilitate the screening of genetic abnormalities, disorders, and diseases like Down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This division also innovates technologies that support genomic workflows, leveraging protein-coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. Revvity serves a diverse clientele, including pharmaceutical and biotechnology firms, laboratories, academic and research institutions, public health authorities, private healthcare organizations, medical professionals, and government bodies.
Get an email when a fund writes about it
Position history
Between Q4 2025 and Q3 2026, 3 fund letters reported a position in Revvity, Inc., with no move described.
| Quarter | Letters | Bought | Sold | Theses |
|---|---|---|---|---|
| Q3 2026 | 1 | 0 | 0 | 0 |
| Q2 2026 | 2 | 0 | 0 | 1 |
| Q4 2025 | 0 | 0 | 0 | 1 |
Fund activity · 3 positions
- July 2026
“Positive performance in the quarter also came via good stock selection within the Health Care sector, with Jazz Pharmaceuticals up 27.5% and Revvity up 27.1%.”
Revvity, Inc. - June 2026
Listed in Guinness Global Quality Mid Cap Fund’s reported holdings.
Revvity, Inc. - June 2026
“As at June 30, 2026, Revvity, Inc. securities were held in EdgePoint Global Portfolio, EdgePoint Canadian Portfolio, EdgePoint Global Growth & Income Portfolio and EdgePoint Canadian Growth & Income Portfolio.”
Revvity, Inc.
Fund coverage · 2 theses
- EdgePoint Global PortfolioJune 2026
Revvity provides tools and services for drug discovery and diagnostics, with acquisitions improving growth and margins and AI potentially accelerating EPS growth.
Read the full thesis - Artisan U.S. Mid-Cap Value StrategyDecember 2025
Revvity Inc is a life sciences and diagnostics company with sticky, high-margin assets and stable diagnostics cash flows trading at a discount to peers.
Read the full thesis
Read every full thesis on Revvity, Inc.
Unlock all 2 theses — the full reasoning behind what funds are buying, plus unlimited access to the entire archive.
View plans→